ELEKTA (EKTAY) Cut to “Neutral” at J P Morgan Chase & Co
ELEKTA (NASDAQ:EKTAY) was downgraded by analysts at J P Morgan Chase & Co from an “overweight” rating to a “neutral” rating in a research note issued on Monday.
Separately, Zacks Investment Research upgraded ELEKTA from a “sell” rating to a “hold” rating in a research report on Monday, August 7th.
Shares of ELEKTA (EKTAY) traded up $0.01 during mid-day trading on Monday, reaching $8.30. The company had a trading volume of 3,240 shares, compared to its average volume of 3,710. ELEKTA has a twelve month low of $7.97 and a twelve month high of $11.18.
TRADEMARK VIOLATION NOTICE: “ELEKTA (EKTAY) Cut to “Neutral” at J P Morgan Chase & Co” was published by Watch List News and is the property of of Watch List News. If you are accessing this report on another site, it was illegally copied and republished in violation of US and international trademark and copyright laws. The original version of this report can be accessed at https://www.watchlistnews.com/elekta-ektay-cut-to-neutral-at-j-p-morgan-chase-co/1700070.html.
Elekta AB (publ) develops and sells clinical solutions for the treatment of cancer and brain disorders worldwide. The company offers Leksell Gamma Knife, a system for cranial stereotactic radiosurgery; the Extend system for utilization of Leksell Gamma Knife Perfexion; and Leksell Stereotactic System for neurosurgery and biopsies.
Receive News & Ratings for ELEKTA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ELEKTA and related companies with Analyst Ratings Network's FREE daily email newsletter.